iTeos Therapeutics (ITOS) News Today $10.15 +0.02 (+0.20%) Closing price 04:00 PM EasternExtended Trading$10.23 +0.08 (+0.83%) As of 06:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ITOS Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period iTeos Therapeutics, Inc. (NASDAQ:ITOS) Given Consensus Rating of "Hold" by BrokeragesAugust 24, 2025 | marketbeat.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITOS and KLG on Behalf of ShareholdersAugust 20, 2025 | prnewswire.comITEOS THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of iTeos Therapeutics, Inc. - ITOSAugust 19, 2025 | globenewswire.comQ3 EPS Estimates for iTeos Therapeutics Increased by WedbushAugust 11, 2025 | marketbeat.comiTeos Therapeutics (NASDAQ:ITOS) Announces Quarterly Earnings Results, Misses Estimates By $0.39 EPSAugust 9, 2025 | marketbeat.comiTeos Therapeutics (NASDAQ:ITOS) Given New $11.00 Price Target at Wells Fargo & CompanyAugust 8, 2025 | marketbeat.comiTeos Therapeutics (ITOS) to Release Earnings on ThursdayAugust 7, 2025 | marketbeat.comiTeos Therapeutics, Inc. (NASDAQ:ITOS) Receives Average Rating of "Hold" from AnalystsJuly 28, 2025 | marketbeat.comReadystate Asset Management LP Sells 26,114 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS)July 25, 2025 | marketbeat.comQ2 EPS Estimate for iTeos Therapeutics Decreased by AnalystJuly 24, 2025 | marketbeat.comQ2 EPS Estimates for iTeos Therapeutics Cut by WedbushJuly 24, 2025 | marketbeat.comPiper Sandler Downgrades iTeos Therapeutics (NASDAQ:ITOS) to HoldJuly 23, 2025 | marketbeat.comWedbush Reaffirms Outperform Rating for iTeos Therapeutics (NASDAQ:ITOS)July 21, 2025 | marketbeat.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITOS and ZIMV on Behalf of ShareholdersJuly 21, 2025 | globenewswire.comALERT: Rowley Law PLLC is Investigating Proposed Acquisition of iTeos Therapeutics, Inc.July 21, 2025 | prnewswire.com$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of iTeos Therapeutics, Inc. (NASDAQ: ITOS)July 21, 2025 | globenewswire.comITOS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of iTeos Therapeutics, Inc. Is Fair to ShareholdersJuly 21, 2025 | tmcnet.comiTeos Therapeutics to be acquired by Concentra BiosciencesJuly 21, 2025 | msn.comiTeos Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $10.047 in Cash per Share Plus a Contingent Value RightJuly 21, 2025 | globenewswire.comPeapod Lane Capital LLC Increases Position in iTeos Therapeutics, Inc. (NASDAQ:ITOS)July 10, 2025 | marketbeat.comiTeos Therapeutics (ITOS): An Example of Biotech LiquidationsJuly 9, 2025 | finance.yahoo.comiTeos Therapeutics, Inc. (NASDAQ:ITOS) Given Consensus Recommendation of "Hold" by BrokeragesJuly 3, 2025 | marketbeat.comITOS iTeos Therapeutics, Inc. - Seeking AlphaJune 26, 2025 | seekingalpha.comiTeos Therapeutics, Inc. (NASDAQ:ITOS) CEO Michel Detheux Sells 43,883 SharesJune 12, 2025 | insidertrades.comiTeos Therapeutics, Inc. (NASDAQ:ITOS) CEO Sells $439,707.66 in StockJune 11, 2025 | marketbeat.comMichel Detheux Sells 43,882 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) StockJune 11, 2025 | marketbeat.comiTeos Therapeutics Inc.June 11, 2025 | barrons.comiTeos Therapeutics validates InvestingPro’s Fair Value analysis with 70% returnJune 9, 2025 | uk.investing.comiTeos Therapeutics, Inc. (NASDAQ:ITOS) Receives Consensus Recommendation of "Hold" from BrokeragesJune 8, 2025 | marketbeat.comInsider Selling: iTeos Therapeutics, Inc. (NASDAQ:ITOS) Director Sells 38,227 Shares of StockJune 7, 2025 | insidertrades.comDavid Hallal Sells 38,227 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) StockJune 6, 2025 | marketbeat.comiTeos Therapeutics, Inc. (NASDAQ:ITOS) Director Sells $391,454.72 in StockJune 6, 2025 | marketbeat.comMichel Detheux Sells 43,883 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) StockJune 6, 2025 | marketbeat.comiTeos Therapeutics, Inc. (NASDAQ:ITOS) CEO Sells $448,035.22 in StockJune 6, 2025 | marketbeat.comStocks With Rising Relative Strength: iTeos TherapeuticsJune 6, 2025 | msn.comNuveen Asset Management LLC Trims Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS)June 6, 2025 | marketbeat.comiTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares Bought by Public Employees Retirement System of OhioJune 5, 2025 | marketbeat.comQ2 EPS Forecast for iTeos Therapeutics Decreased by AnalystJune 2, 2025 | marketbeat.comMillennium Management LLC Has $3.16 Million Stock Position in iTeos Therapeutics, Inc. (NASDAQ:ITOS)June 1, 2025 | marketbeat.comiTeos Therapeutics, Inc. (NASDAQ:ITOS) Position Increased by Ameriprise Financial Inc.June 1, 2025 | marketbeat.comWedbush Lowers Earnings Estimates for iTeos TherapeuticsMay 31, 2025 | marketbeat.comiTeos Therapeutics Announces Intent to Wind Down Operations and Explore Asset Sales to Maximize Shareholder ValueMay 30, 2025 | nasdaq.comiTeos Therapeutics' (ITOS) "Equal Weight" Rating Reaffirmed at Wells Fargo & CompanyMay 29, 2025 | marketbeat.comiTeos Therapeutics (NASDAQ:ITOS) Stock Rating Lowered by WedbushMay 29, 2025 | marketbeat.comWedbush Downgrades iTeos Therapeutics (ITOS)May 29, 2025 | msn.comiTeos Therapeutics stock surges on wind-down newsMay 28, 2025 | za.investing.comiTeos Therapeutics Stock Jumps Following Operational Closure AnnouncementMay 28, 2025 | msn.comiTeos Therapeutics To Wind Down Operations, Explores Asset Sale: Retail Believes It’s ‘Worth More Selling It Off’May 28, 2025 | msn.comiTeos Therapeutics Inc.: iTeos Therapeutics Announces Its Intention to Wind Down OperationsMay 28, 2025 | finanznachrichten.deITeos Therapeutics Shares Surge on Wind Down of OperationsMay 28, 2025 | marketwatch.com Get iTeos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ITOS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ITOS Media Mentions By Week ITOS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ITOS News Sentiment▼1.441.03▲Average Medical News Sentiment ITOS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ITOS Articles This Week▼23▲ITOS Articles Average Week Get the Latest News and Ratings for ITOS and Related Stocks Enter your email address to receive the latest news and analysts' ratings for iTeos Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies DYN News Today APGE News Today TWST News Today BEAM News Today CDTX News Today IMCR News Today BHVN News Today WVE News Today AUPH News Today TVTX News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ITOS) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredWhat Are Some Strategies to Help Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredSmall Washington, DC Group Could Crash US StocksNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iTeos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share iTeos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access